Zevra director granted 30,000 stock options

Zevra Therapeutics director Douglas W. Calder received a grant of stock options as board compensation.

Rhea-AI Filing Summary

Zevra Therapeutics director Douglas W. Calder received a grant of stock options as board compensation. The award covers 30,000 options to buy common stock at an exercise price of $11.17 per share, matching the Nasdaq closing price on June 4, 2026.

All 30,000 options vest 100% on the earlier of the first anniversary of grant, the day before the first annual stockholders meeting after the grant date, or immediately before a change in control, subject to continued service. Following this grant, Calder holds 30,000 options directly.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Calder Douglas W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,000 contracts (Direct)

Footnotes (3)

1. F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.
2. F2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
3. F3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Key Figures

Option grant size: 30,000 options Exercise price: $11.17 per share Options after transaction: 30,000 options +1 more

4 metrics

Option grant size 30,000 options Stock Option (right to buy) granted on June 4, 2026

Exercise price $11.17 per share Equal to Nasdaq closing price on June 4, 2026

Options after transaction 30,000 options Total options held directly following the grant

Option expiration June 3, 2036 Expiration date of the granted stock options

Key Terms

Stock Option (right to buy), exercise price, non-employee director compensation policy, change in control

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

non-employee director compensation policy financial

"pursuant to the Issuer's tenth amended and restated non-employee director compensation policy"

change in control financial

"immediately prior to a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did director Douglas W. Calder receive from Zevra Therapeutics (ZVRA)?

Douglas W. Calder received a grant of 30,000 stock options as compensation for serving on Zevra’s board. These options give him the right to buy 30,000 shares of common stock at a preset exercise price.

What is the exercise price of the new Zevra (ZVRA) stock options?

The exercise price is $11.17 per share, equal to the Nasdaq closing price of Zevra’s common stock on June 4, 2026. This price is the cost per share if Calder later exercises the options.

When do Douglas Calder’s Zevra (ZVRA) options vest?

All 30,000 options vest 100% on the earliest of three dates: the first anniversary of the grant, the day before the first annual stockholders meeting after grant, or immediately before a change in control, assuming continued board service.

How many Zevra (ZVRA) options does Douglas Calder hold after this grant?

After this grant, Douglas Calder holds 30,000 stock options directly. The filing does not list additional derivative positions, indicating this award represents his visible option holdings in the reported data.

Why did Zevra (ZVRA) grant these stock options to Douglas Calder?

The options were granted under Zevra’s tenth amended and restated non-employee director compensation policy. They serve as part of Calder’s compensation for his ongoing service on the company’s board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Calder Douglas W

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

101 FEDERAL STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$11.17(1)	06/04/2026		A		30,000(2)		(3)	06/03/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Douglas W. Calder	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)